<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05094947</url>
  </required_header>
  <id_info>
    <org_study_id>Moscow MSUMD</org_study_id>
    <nct_id>NCT05094947</nct_id>
  </id_info>
  <brief_title>Intermittent Catheterization Versus Trial Without Catheter</brief_title>
  <official_title>Indwelling Urinary Catheterization Versus Clean Intermittent Catheterization for the Management of Acute Urinary Retention: Multicenter, Randomized, Controlled Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Moscow State University of Medicine and Dentistry</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Moscow State University of Medicine and Dentistry</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, comparative, multicenter, randomized controlled trial. The aim of this&#xD;
      study is to compare the efficacy, safety and quality of life within patients with acute&#xD;
      urinary retention managed by the intermittent catheterization compared or indwelling Foley&#xD;
      catheter.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the quality of life</measure>
    <time_frame>2 months</time_frame>
    <description>Assessment of the quality of life according to the SF-36 questionnaire on the first, second, or third day after the start of intermittent catheterization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the restoration of self-urination.</measure>
    <time_frame>2 months</time_frame>
    <description>A positive outcome is considered to be the restoration of independent urination, and the presence of no more than 150 ml of residual urine in a control study 12-24 hours after the restoration of urination.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>intermittent catheterization (group B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Procedure/Surgery: The acute urinary retention in group B is managed by clean intermittent catheterization along with alpha-blockers during 3 period. After 3 days the ability of spontaneous voiding is assessed and registered as an outcome.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Catheter Foley (group A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The acute urinary retention in group A is managed by trial without catheter along with alpha-blockers during 3 period. After 3 days the indwelling Foley catheter is removed and ability of spontaneous voiding is assessed and registered as an outcome.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intermittent catheterization</intervention_name>
    <description>clean intermittent catheterization with catheter Nelaton</description>
    <arm_group_label>intermittent catheterization (group B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>trial without catheter</intervention_name>
    <description>catheter Foley</description>
    <arm_group_label>Catheter Foley (group A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alpha-blockers</intervention_name>
    <description>tamsulosin, alfuzosin, doxazosin, silodosin</description>
    <arm_group_label>Catheter Foley (group A)</arm_group_label>
    <arm_group_label>intermittent catheterization (group B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Men with acute urinary retention due to prostatic hyperplasia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient's with serious conditions and incapacity&#xD;
&#xD;
          -  Previous urethral or prostate surgery.&#xD;
&#xD;
          -  Urethral stricture.&#xD;
&#xD;
          -  Urethrorrhagia.&#xD;
&#xD;
          -  Injuries of urethra and perineum.&#xD;
&#xD;
          -  Attempts of bladder catheterization within 15 days before the acute urinary retention&#xD;
             episode.&#xD;
&#xD;
          -  Urinary tract infection.&#xD;
&#xD;
          -  Neurogenic bladder.&#xD;
&#xD;
          -  Chronic urinary retention with a bladder volume of more than 1 liter.&#xD;
&#xD;
          -  Obstructive uropathy due to the acute urinary retention.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vigen Malkhasyan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moscow state university of medicine and dentistry named after A.I. Evdokimov</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vigen Malkhasyan</last_name>
    <phone>+7(909) 644-16-88</phone>
    <email>vigenmalkhasyan@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sergey Kotov</last_name>
    <phone>+7(965)439-48-39</phone>
    <email>urokotov@mail.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Moscow state university of medicine and dentistry named after A.I. Evdokimov</name>
      <address>
        <city>Moscow</city>
        <zip>127473</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vigen Malkhasyan</last_name>
      <phone>+7(909) 644-16-88</phone>
      <email>vigenmalkhasyan@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Vigen Malkhasyan</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dmitriy Pushkar</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexey Volnukhin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 10, 2021</study_first_submitted>
  <study_first_submitted_qc>October 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Benign prostatic hyperplasia</keyword>
  <keyword>acute urinary retention</keyword>
  <keyword>intermittent catheterization</keyword>
  <keyword>urethral catheter</keyword>
  <keyword>trial without catheter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Urinary Retention</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenergic alpha-Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

